Message Font: Serif | Sans-Serif
No. of Recommendations: 1
CHICAGO (Reuters) - Abbott Laboratories Inc.'s pivotal role in Boston Scientific Corp.'s $80-per-share offer to buy Guidant Corp. signals its determination to be a player in medical devices, regardless of how the bidding match ends, analysts said on Wednesday.

While many Wall Street analysts say Boston Scientific now has the upper hand over Johnson & Johnson with its current bid for Guidant, some believe Abbott's participation -- providing some of the funding for the bid -- suggests Abbott could move in to buy Boston Scientific if it ultimately loses.

"Underneath the covers I believe that Abbott wants to be a device player and for the first time they are making a real legitimate stand to become one. If Boston doesn't get Guidant, at this valuation, I think Abbott ultimately buys Boston," said Jeffries & Co. analyst Ryan Rauch.

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.